原发性局灶不可逆电穿孔治疗局限性前列腺癌的中位5年结局
该研究评估局灶不可逆电穿孔(IRE)作为局限性临床显著前列腺癌(csPCa)原发治疗的中位5年(最长10年)肿瘤学和功能结局。共分析229例患者,中位随访60个月,5年无失败生存率为84%,8年为69%,无转移生存率99.6%,前列腺癌特异性和总生存率均为100%。结论认为局灶IRE在选定患者中提供可接受的局部和远处肿瘤控制,且泌尿和性毒性低于根治性治疗,但需长期随访和外部验证。
要点
- 中位随访60个月,5年无失败生存率84%,8年69%。
- 无转移生存率99.6%(228/229),前列腺癌特异性和总生存率均为100%(229/229)。
- 随访活检发现残留csPCa 24%(45/190),MRI显示完全消融82%(186/226)。
核心结论
- 较长期随访证实,局灶IRE在选定男性中提供可接受的局部和远处肿瘤控制,且泌尿和性毒性低于根治性治疗。
- 需要长期随访和外部验证以确立这种新治疗模式为有效治疗选择。
研究设计与样本
- 回顾性分析2013年2月至2021年8月期间接受局灶IRE作为局限性前列腺癌原发治疗且随访至少12个月的所有患者。
- 共纳入229例患者,中位(IQR)随访60(40-80)个月。
主要发现
- 中位(IQR)年龄68(64-74)岁,中位(IQR)PSA水平5.9(4.1-8.2)ng/mL,86%为中间风险疾病,7%为高风险疾病。
- 38例(17%)进展至根治性治疗,中位(IQR)时间为IRE后35(17-53)个月。
- Kaplan-Meier无失败生存率3年91%、5年84%、8年69%。
- 无转移生存率99.6%(228/229),前列腺癌特异性和总生存率均为100%(229/229)。
- 随访活检发现残留csPCa 24%(45/190),MRI显示完全消融82%(186/226);短期尿控保留(基线98%,3/144;12个月99%,1/131),足够性交的勃起较基线下降13%(71%至58%)。
临床怎么用
- 作者认为,局灶IRE在选定男性中提供可接受的局部和远处肿瘤控制,且泌尿和性毒性低于根治性治疗。
- 作者指出,需要长期随访和外部验证以确立这种新治疗模式为有效治疗选择。
局限性
- 需要长期随访和外部验证以确立这种新治疗模式为有效治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate longer-term oncological and functional outcomes of focal irreversible electroporation (IRE) as primary treatment for localised clinically significant prostate cancer (csPCa) at a median follow-up of 5 years (up to 10 years). PATIENTS AND METHODS: All patients that underwent focal IRE as primary treatment for localised PCa between February 2013 and August 2021 with a minimum 12 months of follow-up were analysed. Follow-up included 6-month magnetic resonance imaging (MRI) and standardised transperineal saturation template ± targeted biopsies at 12 months, and further biopsies in the case of clinical suspicion on serial imaging and/or prostate-specific antigen (PSA) levels. Failure-free survival (FFS) was defined as no progression to radical treatment or nodal/distant disease. Local recurrence was defined as any International Society of Urological Pathology Grade of ≥2 on biopsy. RESULTS: A total of 229 patients were analysed with a median (interquartile range [IQR]) follow-up of 60 (40-80) months. The median (IQR) age was 68 (64-74) years, the median (IQR) PSA level was 5.9 (4.1-8.2) ng/mL, and 86% harboured intermediate-risk disease and 7% high-risk disease. In all, 38 patients progressed to radical treatment (17%), at a median (IQR) of 35 (17-53) months after IRE. Kaplan-Meier FFS rates were 91% at 3 years, 84% at 5 years and 69% at 8 years. Metastasis-free survival was 99.6% (228/229), PCa-specific and overall survival were 100% (229/229). Residual csPCa was found in 24% (45/190) during follow-up biopsy and MRI showed a complete ablation in 82% (186/226). Short-term urinary continence was preserved (98%, three of 144 at baseline, 99%, one of 131 at 12 months) and erections sufficient for intercourse decreased by 13% compared to baseline (71% to 58%). CONCLUSION: Longer-term follow-up confirms our earlier findings that focal IRE provides acceptable local and distant oncological control in selected men with less urinary and sexual toxicity than radical treatment. Long-term follow-up and external validation of these findings, is required to establish this new treatment paradigm as a valid treatment option.
引用
- Scheltema MJ, Geboers B, Blazevski A, et al. Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer. BJU Int. 2022. PMID: 36495481. doi:10.1111/bju.15946
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。